局部炎症介质释放抑制

"局部炎症介质释放抑制" refers to the pharmacological or physiological inhibition of the release of chemical mediators (such as histamine, prostaglandins, leukotrienes, and cytokines) locally at sites of inflammation. Such inhibition can be achieved by targeting various enzymes (like cyclooxygenases or lipoxygenases), receptors (such as histamine or leukotriene receptors), or signaling pathways in immune cells, especially mast cells and macrophages[2][3][4]. The concept is central to anti-inflammatory and anti-allergic therapies, but it is not itself a distinct biochemical entity, receptor, or canonical drug target. Instead, inhibition of mediator release may result from action on diverse biological targets such as cyclooxygenase enzymes (COX-1, COX-2), leukotriene synthesis enzymes, mast cell surface receptors, or cytokine pathways[2][3][4]. In short, "局部炎症介质释放抑制" is a mechanism or process, *not* a discrete, identifiable molecule, protein, or receptor. For structured drug discovery or bioinformatics workflows, a more precise molecular target name (such as "histamine H1 receptor," "cyclooxygenase-2," or "interleukin-1 beta") should be used[2][3][4].

Other names

Inhibition of inflammatory mediator releaseSuppression of local inflammatory mediator release

Inhibition of mediator synthesis (e.g., prostaglandins, leukotrienes) Blockade of mediator release (e.g., inhibition of histamine release from mast cells) Suppression of cytokine production